8-K: LifeMD Q3 2025: Revenue Up, Debt Paid, Telehealth Focus

LifeMD, Inc. reported a 13% year-over-year revenue increase to $60.2 million in Q3 2025, alongside a 20% rise in adjusted EBITDA and the complete payoff of outstanding debt.

Summary

• Total revenue increased 13% year-over-year to $60.2 million for the third quarter of 2025.
• Adjusted EBITDA rose 20% year-over-year to $5.1 million for the third quarter of 2025.
• Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million for the third quarter of 2025.
• All outstanding debt, approximately $17 million, was paid off during the third quarter.
• Subsequent to quarter-end, the majority stake in WorkSimpli was fully divested, positioning LifeMD as a pure-play telehealth and pharmacy platform.
• The number of active telehealth subscribers increased 14% to approximately 310,000 at quarter-end.
• GAAP net loss was $4.6 million or ($0.10) per share, an improvement from a net loss of $5.4 million or ($0.13) per share in the prior-year period.
• Cash totaled $23.8 million as of September 30, 2025.
• The RexMD business returned to growth and added nearly 10,000 net new subscribers in the quarter.
• Regulatory approval was achieved for a Pennsylvania-based 503-A compounding pharmacy, which is currently licensed in 14 states with aggressive pursuit of licensure in all 50 states.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue and EBITDA growth in its core telehealth business, significantly improved its balance sheet by paying off all debt and divesting a non-core asset, and showed promising diversification. While gross margin slightly declined and the GLP-1 market is competitive, the overall strategic direction and financial performance are positive.

Positives

• Total revenue increased 13% year-over-year to $60.2 million for Q3 2025.
• Adjusted EBITDA increased 20% year-over-year to $5.1 million for Q3 2025.
• Telehealth revenue grew 18% to $47.3 million for Q3 2025.
• Telehealth adjusted EBITDA increased 30% to $2.9 million for Q3 2025.
• All outstanding debt, approximately $17 million, was paid off during the quarter, significantly strengthening the balance sheet.
• The divestiture of WorkSimpli transforms LifeMD into a pure-play telehealth and pharmacy platform.
• Active telehealth subscribers increased 14% to approximately 310,000 at quarter-end.
• GAAP net loss improved to $4.6 million ($0.10 per share) from $5.4 million ($0.13 per share) in the prior year.
• The RexMD business returned to growth, adding nearly 10,000 net new subscribers.
• Regulatory approval for a Pennsylvania-based 503-A compounding pharmacy enhances competitive positioning, improves cost structure, and patient experience.
• Year-to-date telehealth Adjusted EBITDA profitability is up 294% versus the prior year.

Negatives

• Gross margin decreased to 88% from 91% in the prior-year period due to revenue mix.
• Telehealth gross margin, excluding WorkSimpli, was 86% compared to 89% in the year-ago period due to revenue mix.
• The weight management market remained challenging due to fierce competition from low-price compounded GLP-1 providers.
• GAAP net loss of $4.6 million for the quarter and $7.9 million for the nine months ended September 30, 2025.
• Litigation costs of $959,802 for the quarter and $1,699,462 for the nine months ended September 30, 2025, related to class action complaints and an executive separation agreement.
• A loss on debt extinguishment of $1,155,851 was recorded.

Risks

• Forward-looking statements are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control.
• Actual results, performance, and financial condition may differ materially from those indicated in forward-looking statements.
• Risks and uncertainties include, but are not limited to, Risk Factors identified in filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto.
• The weight management market remains challenging due to fierce competition from low-price compounded GLP-1 providers.
• Ongoing class action complaints (Johnston v. LifeMD, Inc., et al. and Marden v. LifeMD, Inc.) alleging violations of securities laws and unauthorized disclosure of information.

Future Outlook

LifeMD expects the GLP-1 market to evolve rapidly in 2026 with product innovation and improved pricing, positioning the company to capitalize on these trends and accelerate growth. The company anticipates continued diversification of its platform, with strong early traction in behavioral health, women's health, men's hormone therapy, and personalized compounded ED therapies. For Q4 2025, revenue is projected to be in the range of $45 million to $46 million and Adjusted EBITDA in the range of $3 million to $4 million. Full-year 2025 guidance is for revenue in the range of $192 million to $193 million (reflecting an approximate 24% increase versus 2024) and Adjusted EBITDA in the range of $13.5 million to $14.5 million (reflecting an approximate 254% increase versus 2024), with both reflecting the pure-play telehealth focus post-WorkSimpli divestiture.

Management Comments

• "While the weight management market remained challenging, driven largely by fierce competition from low-price compounded GLP-1 providers, our business continued to demonstrate real strength." Justin Schreiber, Chairman and CEO.
• "We expect the GLP-1 market to evolve rapidly in the year to come as product innovation and improved pricing expand access, and we believe LifeMD is uniquely positioned to capitalize on these trends and accelerate growth in 2026." Justin Schreiber, Chairman and CEO.
• "We are seeing strong early traction in behavioral health, womens health, mens hormone therapy, and personalized compounded ED therapies." Justin Schreiber, Chairman and CEO.
• "Our RexMD business returned to growth and added nearly 10,000 net new subscribers in the quarter." Justin Schreiber, Chairman and CEO.
• "We also achieved a major milestone with the regulatory approval of our Pennsylvania-based 503-A compounding pharmacy. We are currently licensed in 14 states and are aggressively pursuing licensure in all 50 states." Justin Schreiber, Chairman and CEO.
• "Subsequent to quarter end, we completed the divestiture of our majority ownership in WorkSimpli, which transformed LifeMD into a pure-play virtual care and pharmacy platform and significantly strengthened our balance sheet." Justin Schreiber, Chairman and CEO.
• "As we look to 2026, we believe LifeMD remains very well positioned with a strong balance sheet, an increasingly diversified virtual care and pharmacy platform and a full suite of industry-leading capabilities to accelerate our growth." Justin Schreiber, Chairman and CEO.
• "Third quarter results for our telehealth business on a stand-alone basis were solid with revenue increasing 18% and adjusted EBITDA increasing 30% versus the prior year period." Marc Benathen, CFO.
• "Importantly, our RexMD business returned to sequential growth in both revenue and patient subscriber count." Marc Benathen, CFO.
• "Additionally, we took major steps to significantly strengthen the companys balance sheet and liquidity including paying off all outstanding debt and the divestiture of our majority interest in WorkSimpli subsequent to quarter end." Marc Benathen, CFO.
• "We have also continued to make significant strides in the companys ongoing telehealth business profitability with year-to-date telehealth Adjusted EBITDA profitability up 294% versus year." Marc Benathen, CFO.

Industry Context

The telehealth industry continues to see strong growth, particularly in specialized areas like weight management, men's and women's health, and behavioral health. LifeMD's focus on diversifying its clinical platform and expanding its compounding pharmacy capabilities aligns with the trend towards integrated virtual care models that offer personalized therapies. The challenging weight management market, specifically due to competition from low-price compounded GLP-1 providers, highlights the competitive pressures within this high-growth segment. The company's strategic shift to a pure-play telehealth and pharmacy platform reflects a broader industry move towards specialization and vertical integration to enhance competitive positioning and cost efficiency.

Comparison to Industry Standards

• The filing does not provide specific comparisons to global benchmarks or named comparable companies, projects, or results.

Legal Proceedings

• A class action complaint captioned Johnston v. LifeMD, Inc., et al., alleging violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 for making false and misleading statements, and violations of Section 20(a) of the Securities Exchange Act of 1934 by individual officer defendants.
• A class action complaint captioned Marden v. LifeMD, Inc., alleging, among other things, unauthorized disclosure of certain information of class members to third parties.
• Costs related to a heavily negotiated executive separation agreement.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue and EBITDA growth, significant debt reduction, strategic focus on core telehealth, and an improved balance sheet. Potential for accelerated growth in 2026.
• Customers/Patients: Enhanced patient experience and access to personalized therapies through the new compounding pharmacy and diversified clinical platform.
• Employees: Strategic focus on telehealth may lead to growth opportunities within the core business.
• Creditors: Positive impact from the payoff of all outstanding debt, reducing financial risk.

Next Steps

• Capitalize on evolving GLP-1 market trends and accelerate growth in 2026.
• Continue diversifying the clinical platform with new launches in areas like women's health, men's health, and psychiatry.
• Aggressively pursue 50-state licensure for the Pennsylvania-based 503-A compounding pharmacy.
• Host a conference call on November 17, 2025, at 4:30 p.m. Eastern time to discuss results and outlook.

Key Dates

Recommendation

The company delivered strong Q3 2025 results with significant year-over-year growth in total revenue (13%) and adjusted EBITDA (20%), particularly in its core telehealth segment (18% revenue, 30% adjusted EBITDA). The strategic divestiture of WorkSimpli and the complete payoff of all outstanding debt (approximately $17 million) dramatically strengthens the balance sheet and positions LifeMD as a focused, pure-play virtual care and pharmacy platform. The return to growth for RexMD and the regulatory approval of a compounding pharmacy are key operational milestones that enhance competitive positioning and future growth prospects. While the GLP-1 market is competitive, management's outlook for 2026 growth and diversification initiatives are compelling. The improved GAAP net loss further underscores positive momentum. These factors collectively suggest a strong positive trajectory for the company.

Keywords

telehealth, virtual primary care, pharmacy platform, weight management, GLP-1, mens health, womens health, behavioral health, compounding pharmacy, RexMD, adjusted EBITDA, revenue growth, debt payoff, WorkSimpli divestiture, LFMD, Q3 2025 earnings